prod:prod_dcx-login
A Better Way to Effective Patient Management
We all know patients don’t get sick on our schedules. They come to us when they need care — 24 hours a day, 365 days a year. Cepheid’s GeneXpert® System was designed with this in mind — to meet the demands of unpredictable test volumes and deliver fast answers for maximum impact on patient care. With nearly 30 available CE-IVD tests, Cepheid is your partner for empowering clinicians with fast, accurate results.
Video
Australian Hospital Emergency Department leverages GeneXpert® for rapid flu testing
St Vincent’s Hospital Pathology (Melbourne, Australia) supports Emergency Department by delivering rapid flu testing with Cepheid's GeneXpert® System.
Video
Cepheid GeneXpert — A Game Changing Testing Platform
Become an Xpert with our 2 minute video! Learn how bringing products like Xpert® CT/NG* (Chlamydia and Gonorrhea) testing in office can be the game changer you need!
Video
Australian Hospital Emergency Department leverages GeneXpert® for rapid flu testing
St Vincent’s Hospital Pathology (Melbourne, Australia) supports Emergency Department by delivering rapid flu testing with Cepheid's GeneXpert® System.
Video
Cepheid GeneXpert — A Game Changing Testing Platform
Become an Xpert with our 2 minute video! Learn how bringing products like Xpert® CT/NG* (Chlamydia and Gonorrhea) testing in office can be the game changer you need!
Webinars
Bringing Molecular Testing Closer to the Patient
Over the past 20 years, there has been a continuous shift toward the decentralization of clinical laboratory testing. With recent advances in the speed and accuracy of point-of-care tests, it is now possible to bring molecular infectious disease testing closer to the patient. This webinar explores the benefits of molecular point-of-care testing as a means of improving patient outcomes and quality of care. Currently available testing methods are reviewed, with an emphasis on the importance of lab testing in the era of performance-driven healthcare.
More...
Simplification of testing and treatment in the quest to eliminate hepatitis C infection
Globally, 71 million people are living with hepatitis C virus (HCV) infection, but the burden of HCV continues to increase. Between 2015 and 2030, WHO targets include reducing new HCV infections by 80% and HCV deaths by 65%, and increasing HCV diagnoses from <20% to 90% and the number of eligible persons receiving HCV treatment from <10% to 80%. To achieve these targets, targeted interventions are needed to enhance HCV testing, linkage to care, and treatment (“the HCV care cascade”). This presentation reviews available evidence on strategies that have been successfully used to enhance HCV testing, linkage to care.
More...
Early diagnosis of HIV and use of molecular Point-of-Care HIV testing as part of a comprehensive strategy to end HIV transmission
According to UNAIDS1 the world is embarking on a Fast-Track strategy to end the AIDS epidemic by 2030. There is a strong global consensus that powerful tools now exist to end the AIDS epidemic. HIV treatment can dramatically extend the lifespan of people living with HIV and effectively prevent HIV transmission. HIV testing is a crucial element, where a positive result offers the opportunity to start treatment as soon as possible and a confirmed negative result opens the possibility to start quickly with Pre-Exposure Prophylaxis (PrEP). On the other side, HIV programs will only be effective if community groups and organisations are part of the implementation. This webinar will explore the benefits of molecular Point-Of-Care HIV testing, within the context of a community centre for men who have sex with men (MSM) and Transgender Women (TW), for three different applications: confirmation of a positive HIV rapid test, detection of an acute HIV infection, and screening of acute infections at the start of PrEP. 1 http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf CE-IVD. In Vitro Diagnostic Medical Device. Not all tests available in all countries. Not available in the U.S.
More...
The Neglected STI: Trichomonas vaginalis
Among US women ages 14-49 the prevalence of Trichomonas vaginalis infection is estimated to be 2.3 million, though 85% of women found to have trichomoniasis report no symptoms. With varied complications such as increased risk of HSV-2/HIV acquisition, pelvic inflammatory disease and pre-term birth it has become increasingly important to identify and treat these patients quickly. This webinar will explore the renewed interest to screen and diagnose T. vaginalis in women. It will examine current testing methods available and provide updates regarding treatment options.
More...
Chlamydia and Gonorrhea testing in the ED and the Need for Evidence Based Medicine
In this webinar, Dr. Larissa May will discuss the diagnosis of sexually transmitted infections in the Emergency Department, the need for evidence-based medicine, and how same-visit treatment and management can be facilitated with on-demand testing for CT/NG.
More...
Key Links
Cepheid GeneXpert® Systems
